Skip to main content
To the Editor: We thank Drs. Gupta, Gupta, and Avasthi for commenting on our data. Dr. Gupta et al. point out that the different attrition rates of the patients who were and were not taking benzodiazepines 3 months after the taper may have affected our success rates at 12 months. Indeed, this was true for the patients taking benzodiazepines but not for the patients who were free of benzodiazepines at 3 months. When we carried forward 3-month data to 12 months for the patients who were not available at the 12-month follow-up, our rate of successful tapers remained at 83% for the patients who were not taking benzodiazepines at 3 months, but it decreased from 41.2% to 25.0% for the patients who were taking benzodiazepines at 3 months. The use of a data set from the last observation carried forward thus leads to a lower rate of success at 12 months than was originally reported for the patients who were unsuccessful in their taper attempt, making our rates of successful benzodiazepine taper even more remarkable.
We apologize for not having used the phrase “random assignment” when describing our double-blind treatment methods. Indeed, the patients were assigned to the three treatments according to a random-assignment schedule, which resulted in three treatment groups of equal sizes. In terms of potential predictors of a successful taper, Dr. Gupta et al. wonder why we did not use the level of baseline symptoms as a potential predictor. We did not do so because depressive symptoms at baseline did not correlate significantly (p<0.10) with treatment outcome and, thus, as we stated in the article, did not fulfill our criteria for variables entered into the logistic regression analysis. We believe that the other comments made by Dr. Gutpa and colleagues, as they relate to the study group, the generalizability of the results, benzodiazepine dependence, long-term treatment for generalized anxiety disorder, resistance to benzodiazepine therapy, and the effect of treatment group on benzodiazepine status at 12 months, were adequately covered in the article.

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 321-a - 322

History

Published online: 1 February 2002
Published in print: February 2002

Authors

Affiliations

NICKOLAS DEMARTINIS, M.D.
J. FELIPE GARCÍA-ESPAÑA, PH.D.
DAVID J. GREENBLATT, M.D.
LAURA MANDOS, PHARM.D.
MOIRA RYNN, M.D.
Philadelphia, Pa.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share